Endogenex vs Epic Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Endogenex develops the ReCET System, a catheter-based endoscopic device that remodels duodenal tissue to treat Type 2 diabetes without surgery; raised $25M Series B in 2024; completed European clinical trials with positive glycemic outcomes;
About
Endogenex is a medical device company headquartered in New Hope, Minnesota, developing endoscopic therapies for metabolic diseases. Its flagship product, the ReCET (Re-Cellularization via Electroporation Therapy) System, uses a catheter-based approach to deliver controlled electrical pulses to the duodenal lining. This non-surgical procedure remodels the duodenal epithelium — the tissue layer believed to play a key role in insulin resistance and glucose regulation — restoring more normal metabolic signaling without removing or bypassing anatomy.
Epic holds over 42% of U.S. acute care hospital EHR market share and is embedding AI across 150+ clinical workflows for 2026, while facing antitrust scrutiny.
About
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale electronic health record systems and reports that more than 305 million patients have a record in Epic, covering the majority of U.S. academic medical centers and large health systems including Kaiser Permanente, Mayo Clinic, Johns Hopkins, and Cleveland Clinic. Epic commands approximately 42% of U.S. acute care hospitals and nearly 55% of acute care hospital beds, making it the undisputed market leader in enterprise EHR.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.